α1-Adrenoceptors and muscarinic receptors in voiding function - binding characteristics of therapeutic agents in relation to the pharmacokinetics.
In vivo and ex vivo binding of α(1)-adrenoceptor and muscarinic receptors involved in voiding function is reviewed with therapeutic agents (α(1)-adrenoceptor antagonists: prazosin, tamsulosin and silodosin; and muscarinic receptor antagonists: oxybutynin, tolterodine, solifenacin, propiverine, imiafenacin and darifenacin) in lower urinary tract symptoms. This approach allows estimation of the inhibition of a well-characterized selective (standard) radioligand by unlabelled potential drugs or direct measurement of the distribution and receptor binding of a standard radioligand or radiolabelled form of a novel drug. In fact, these studies could be conducted in various tissues from animals pretreated with radioligands and/or unlabelled novel drugs, by conventional radioligand binding assay, radioactivity measurement, autoradiography and positron emission tomography. In vivo and ex vivo receptor binding with α(1)-adrenoceptor antagonists and muscarinic receptor antagonists have been proved to be useful in predicting the potency, organ selectivity and duration of action of drugs in relation to their pharmacokinetics. Such evaluations of drug-receptor binding reveal that adverse effects could be avoided by the use of new α(1)-adrenoceptor antagonists and muscarinic receptor antagonists for the treatment of lower urinary tract symptoms. Thus, the comparative analysis of α(1)-adrenoceptor and muscarinic receptor binding characteristics in the lower urinary tract and other tissues after systemic administration of therapeutic agents allows the rationale for their pharmacological characteristics from the integrated viewpoint of pharmacokinetics and pharmacodynamics. The current review emphasizes the usefulness of in vivo and ex vivo receptor binding in the discovery and development of novel drugs for the treatment of not only urinary dysfunction but also other disorders.
Department of Pharmacokinetics and Pharmacodynamics and Global Center of Excellence Program, School of Pharmaceutical Sciences, University of Shizuoka, Yada, Shizuoka 422-8526, Japan. yamada@u-shizuoka-ken.ac.jp
Shizuo
S
Yamada
Yoshihiko
Y
Ito
Hideo
H
Tsukada
D000317:Adrenergic alpha-Antagonists / Q000493:pharmacokinetics*; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000378:metabolism*; D018727:Muscarinic Antagonists / Q000493:pharmacokinetics*; D018340:Receptors, Adrenergic, alpha-1 / Q000378:metabolism*; D011976:Receptors, Muscarinic / Q000378:metabolism*; D053201:Urinary Bladder, Overactive / Q000378:metabolism*; D014555:Urination Disorders / Q000378:metabolism*
D000317:Adrenergic alpha-Antagonists; D018727:Muscarinic Antagonists; D018340:Receptors, Adrenergic, alpha-1; D011976:Receptors, Muscarinic
Brain Res Mol Brain Res. 2005 Jan 5;133(1):6-11
15661360
Neurobiol Aging. 2009 Mar;30(3):337-52
17869382
Eur J Pharmacol. 1993 Nov 16;249(3):307-15
7904564
Eur Urol. 2006 Aug;50(2):317-26
16687205
Clin Pharmacokinet. 2006;45(4):325-50
16584282
Am J Obstet Gynecol. 2010 Apr;202(4):378.e1-7
20042169
Br J Pharmacol. 1999 May;127(1):19-26
10369451
Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6
19446545
Int J Clin Pract. 2007 Aug;61(8):1294-300
17627708
J Am Geriatr Soc. 1998 Jan;46(1):8-13
9434659
Br J Pharmacol. 1997 Jan;120(2):231-8
9117115
Curr Pharm Des. 2001 Dec;7(18):1907-29
11772357
Low Urin Tract Symptoms. 2010 Apr;2(1):43-9
26676219
Eur J Pharmacol. 2006 Jan 4;529(1-3):157-63
16316647
Mol Pharmacol. 1995 Aug;48(2):250-8
7651358
Biol Pharm Bull. 1999 Apr;22(4):412-7
10328564
Br J Pharmacol. 2006 Feb;147 Suppl 2:S88-119
16465187
Eur J Pharmacol. 1998 Jan 19;342(1):85-92
9544796
Clin Ther. 2005 Feb;27(2):144-53
15811477
Br J Pharmacol. 2009 Apr;156(7):1147-53
19378377
Int J Urol. 1994 Sep;1(3):203-11
7542152
J Urol. 2007 Feb;177(2):766-70
17222678
Ann Nucl Med. 2008 Jun;22(5):447-55
18600425
J Pharmacol Exp Ther. 1992 Oct;263(1):201-6
1357156
J Pharmacol Exp Ther. 1999 Jun;289(3):1575-83
10336555
Eur J Pharmacol. 1996 Nov 7;315(1):73-9
8960867
Life Sci. 1998;63(24):2147-55
9851306
J Urol. 1999 Jun;161(6):1809-12
10332441
Pharmacol Toxicol. 1997 Oct;81(4):169-72
9353847
Psychopharmacology (Berl). 1992;107(2-3):437-41
1615141
Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6):463-71
18074121
J Pharmacol Exp Ther. 2006 Mar;316(3):1137-45
16282521
Int J Urol. 2009 May;16(5):499-506
19389083
Drugs Aging. 1995 Mar;6(3):243-62
7620236
Pharmacol Rev. 1995 Jun;47(2):267-70
7568329
Auton Neurosci. 2005 Oct 30;122(1-2):9-20
16125470
J Urol. 2001 Jul;166(1):140-5
11435842
Eur J Pharmacol. 1997 May 30;327(2-3):195-207
9200560
N Engl J Med. 2004 Feb 19;350(8):786-99
14973214
Life Sci. 2006 Dec 14;80(2):127-32
16996089
Arzneimittelforschung. 2001 Feb;51(2):125-33
11258042
Adv Drug Deliv Rev. 1999 Apr 5;37(1-3):175-188
10837734
Br J Pharmacol. 2005 May;145(2):219-27
15753946
BJU Int. 1999 Oct;84(6):646-51
10510109
Life Sci. 1998;62(17-18):1585-9
9585140
BMC Fam Pract. 2009 Jan 23;10:8
19166611
J Am Geriatr Soc. 2005 Dec;53(12):2195-201
16398909
J Pharmacol Exp Ther. 1994 Aug;270(2):722-7
8071865
Drugs Aging. 2001;18(4):277-304
11341475
J Pharmacol Exp Ther. 1997 Jan;280(1):1-5
8996174
Drug Metab Dispos. 1998 Apr;26(4):289-93
9531513
Arzneimittelforschung. 2007;57(3):147-54
17469649
J Urol. 2005 Jun;173(6):2048-53
15879823
Naunyn Schmiedebergs Arch Pharmacol. 1985 Jul;330(1):16-21
2864637
Am J Physiol Renal Physiol. 2004 Nov;287(5):F1084-91
15251862
Life Sci. 2010 Jul 31;87(5-6):175-80
20598326
Eur J Pharmacol. 1999 Jun 25;374(3):495-502
10422795
J Pharmacol Exp Ther. 2011 Feb;336(2):365-71
21047953
Urology. 2003 Aug;62(2):237-42
12893326
Nucl Med Biol. 2004 Jul;31(5):583-90
15219276
Biol Pharm Bull. 2001 May;24(5):491-5
11379767
Life Sci. 1994;54(24):1845-54
7515140
Brain Res Brain Res Rev. 1992 Sep-Dec;17(3):215-26
1467811
Neurosci Lett. 2008 May 2;436(1):81-4
18372110
Drug Metab Dispos. 2010 Aug;38(8):1314-21
20483954
J Urol. 1997 Mar;157(3):1093-7
9072550
Eur J Pharmacol. 2007 Feb 28;557(2-3):154-8
17207478
Life Sci. 1992;50(2):127-35
1370569
Urology. 2010 Oct;76(4):1017.e7-12
20719367
J Pharmacol Exp Ther. 2008 Jun;325(3):774-81
18326811
Naunyn Schmiedebergs Arch Pharmacol. 1995 Jul;352(1):1-10
7477417
Naunyn Schmiedebergs Arch Pharmacol. 1993 Oct;348(4):385-95
7506392
J Pharmacol Sci. 2010;112(2):142-50
20134113
J Pharm Pharmacol. 2002 Jul;54(7):975-82
12162717
J Pharmacol Exp Ther. 1997 Jul;282(1):228-35
9223558
Br J Pharmacol. 1993 May;109(1):80-7
8098642
Spinal Cord. 1999 Mar;37(3):196-200
10213329
Int J Urol. 2008 Oct;15(11):986-91
18761536
J Urol. 2006 Jan;175(1):365-9
16406943
Nat Biotechnol. 2000 Jun;18(6):655-60
10835605
Arzneimittelforschung. 2007;57(2):92-100
17396619
Life Sci. 2005 Apr 8;76(21):2445-56
15763076
Lancet Neurol. 2004 Jan;3(1):46-53
14693111
BMJ. 2006 Feb 25;332(7539):455-9
16452102
World J Urol. 2002 Apr;19(6):390-6
12022707
J Pharmacol Exp Ther. 1999 Oct;291(1):81-91
10490890
Br J Pharmacol. 1995 Jul;115(6):981-6
7582530
J Pharmacol Exp Ther. 2001 Jan;296(1):160-7
11123376